Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
AIM listed biotech Reneuron (RENE) has today announced that it has completed the move of all of its operations from Surrey to Pencoed, Bridgend, Wales. Hooray...welcome to the most expensive job creation programme in history paid for with YOUR money.
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments
turbograndad
Tom, Its all in the future dreams and aspiration nation, look you boyo. You can’t keep shagging sheep, and producing noncompetitive steel, with the Chinese dumpathon. This free market, has to be paid for at the end of the day, look at all the preferential s you southern jessy’s get, especially it that there London.
BlueFrew
Minor point, but an important one. It isn’t the English taxpayer (do the thieving crony capitalists in the city as English taxpayers by the way?). It’s deficit spending. £3.7 billion doesn’t even touch the sides of the hole that we are in.
turbograndad
Anyway when did economics come into it, it’s politics, so put it on the tab.
Alquemie
Tom, it’s not so much about job creation but the Welsh Assembly’s desperate attempt to be able claim that it has a “thriving” life science sector.
Probably all coincidence, but the Welsh Life Science Investment fund is managed by Sir Chris “ Cut me and do I not bleed Port Talbot” Evan’s Arthurian fund. That’s the same Sir Chris that sits on Reneuron’s board as a NED and bought 9.6m shares at the time of the Welsh Assembly commitment (which I believe was £13.8m: £7.8m in non-dilutive grants plus £5m equity investment) as well as persuading Martin Walton (the current Arthurian CEO, then at Excalibur) and others to pony up for another 12m or so shares. Another current Arthurian, Trevor Jones was Reneuron’s Chairman until 2012.
GreedSpam
Woodford again. No surprise that ReNeuron is quite a large holding in none other than the Woodford Patient Capital Trust. – Add that to the dog tags and the list. So if it is a waste of taxpayers cash then surely it is a waste of YOU investors cash too? Kind of like a double waste – you paid tax on your savings and then give it to this guy who goes off and gambles it all. Is it dodgy? If not then put me forward as BBM of the week.
Msmadi
You’re quite a disappointment Tom – many rely on people like you for advice and direction but your choice of words is appauling, not to mention completely discrediting you and shareprophets. Such a shame ….
Tom Winnifrith
Msmadi
Shucks I am gutted. Not. As I have explained numerous times I write for my pleasure. If folks want to read me that is their call. My intent is to please me not others. If you dont like this site fuck off & see if I care
Best wishes
Tom
Alquemie
Watchdog finds ‘significant shortcomings’ with government handling of biotech VC fund.
Shock. Gasp. Disbelief……
http://www.fiercebiotech.com/story/watchdog-finds-significant-shortcomings-handling-government-biotech-vc-fund/2016-03-02